Daniel Humberto Pozza, Ramon Andrade De Mello*, Raphael L.C. Araujo and Vamsidhar Velcheti Pages 372 - 381 ( 10 )
Background: Lung cancer (LC) development is a process that depends on genetic mutations. The DNA methylation, an important epigenetic modification, is associated with the expression of noncoding RNAs, such as microRNAs. MicroRNAs are particularly essential for cell physiology, since they play a critical role in tumor suppressor gene activity. Furthermore, epigenetic disruptions are the primary event in cell modification, being related to tumorigenesis. In this context, microRNAs can be a useful tool in the LC suppression, consequently improving prognosis and predicting treatment.
Conclusion: This manuscript reviews the main microRNAs involved in LC and its potential clinical applications to improve outcomes, such as survival and better quality of life.
Lung cancer, squamous cell carcinoma, adenocarcinoma, epigenetic modification, DNA methylation, microRNA.
Departamento de Biomedicina da Faculdade de Medicina, and Faculdade de Ciencias da Nutricao e Alimentacao, and I3s, Universidade do Porto, Porto, Algarve Biomedical Centre, Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Department of Oncology, Albert Einstein Israelite Hospital, Sao Paulo, Thoracic Oncology Program, NYU Langone, Perlmutter Cancer Center, New York, NY, 10016